A Letter to the FDA Regarding iQOS, a Less Harmful Alternative to Cigarettes
Alex Brill and Sally Satel | Letter to commissioner of the FDA
Dear Dr. Gottlieb:
We are scholars at the American Enterprise Institute, a nonpartisan, nonprofit policy research entity. Dr. Satel is a practicing psychiatrist who has studied and researched a broad range of matters related to mental health policy and addiction, including tobacco harm reduction. Mr. Brill is an expert in public finance and health economics, with a concentration in the economic and public health implications of smoking and its alternatives. The views expressed here are ours alone and may or may not reflect the views of our colleagues.
Thank you for the opportunity to comment on the modified risk tobacco product (MRTP) applications by Philip Morris Products S.A. cited above under section 911(g) of the Federal Food, Drug and Cosmetic Act. Philip Morris is seeking approval to make specific claims about risks of its heat-not-burn (HNB) technology (commercially known as iQOS) relative to conventional cigarettes. We urge the FDA to expeditiously review these applications and permit the sale and marketing of iQOS to American consumers.
